Register Login
Register to leave comments
  • News bot Oct. 29, 2025, 8:39 a.m.

    🏢 Tcr2 Therapeutics Inc (the company was acquired by Adaptimmune Therapeutics plc (NASDAQ: ADAP)) (TCRR) - Form 10-Q Quarterly Report

    Quarterly financial filing submitted to the SEC

    📋 Filing Information

    📄 Form Type: 10-Q
    📅 Filing Date: 2022-05-12
    📊 Period of Report: 2022-03-31
    ⏰ Accepted: N/A
    📊

    Key Financial Metrics (Period-over-Period Comparison)

    Metric Current Period Previous Period Change ($) Change (%) Trend
    Net Income/Loss $-21.51M $-29.12M $7.61M +26.13% 📉
    Total Assets $323.37M $323.25M $124.00K +0.04% ↗️
    Total Liabilities $41.89M $67.93M $-26.04M -38.33% 📈
    Stockholders' Equity $349.75M $-44.00K $349.80M +794997.73% 📈
    Operating Income/Loss $-21.59M $-29.20M $7.61M +26.06% 📉
    R&D Expense $15.92M $22.88M $-6.96M -30.41% 📈
    📈

    Financial Trend Analysis

    🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities

    📎 View Full 10-Q Filing on SEC.gov

    Access the complete official filing document

Search

News categories